http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101187576-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2011-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101187576-B1 |
| titleOfInvention | Novel Use of Erythrocyte Differentiation Regulator 1 as Cancer Treatment |
| abstract | The present invention relates to a novel use of erythrocyte differentiation regulator 1 as a cancer treatment agent, and more specifically, to Erdr1 or a composition for preventing and inhibiting cancer metastasis, comprising Erdr1 or an expression vector comprising a polynucleotide encoding the same as an active ingredient. Or it relates to a method for screening a composition for preventing and treating cancer or a substance for inhibiting cancer metastasis or cancer cell migration comprising an expression vector thereof. Erdr1 in the present invention is negatively regulated by IL-18 expression, and regulates the expression of HSP90 and the generation of ROI to inhibit the migration, invasion and metastasis of cancer or tumor cells, Erdr1 recombinant protein is a cancer cell of natural killer cells Therefore, the expression vector and the recombinant protein comprising the Erdr1 or the polynucleotide encoding the same of the present invention inhibit cancer metastasis and have an immune cell activating effect to be useful for the prevention and treatment of cancer. The antibody against the Erdr1 protein may be used as a cancer diagnostic composition. |
| priorityDate | 2010-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 187.